NTLA 16.31 ▼ -1.81% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Intellia Therapeutics Inc...

    NASDAQ: NTLA · Real-Time Price · USD
    16.31
    -0.30 (-1.81%)
    At close: Sep 26, 2025, 3:59 PM
    16.29
    -0.12%
    After-hours: Sep 26, 2025, 07:50 PM EDT
    -1.81%
    Bid 15.98
    Market Cap 1.75B
    Revenue (ttm) 52.86M
    Net Income (ttm) -480.19M
    EPS (ttm) -4.69
    PE Ratio (ttm) -3.48
    Forward PE -4.6
    Analyst Buy
    Dividends n/a
    Ask 16.39
    Volume 5,396,561
    Avg. Volume (20D) 5,152,052
    Open 16.56
    Previous Close 16.61
    Day's Range 15.44 - 16.62
    52-Week Range 5.90 - 21.47
    Beta 2.28
    Ex-Dividend Date n/a

    About NTLA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol NTLA
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for NTLA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Intellia Therapeutics Inc. is scheduled to release its earnings on Nov 6, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 week ago
    +29.81%
    Intellia Therapeutics shares are trading higher af... Unlock content with Pro Subscription
    4 months ago
    -22.88%
    Intellia Therapeutics shares are trading lower after the company said that a single, recent, asymptomatic patient has had grade 4 liver transaminase elevations based on laboratory tests in its Phase 3 MAGNITUDE study.
    news image

    2 days ago · benzinga.com

    Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

    Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary...

    news image

    1 week ago · seekingalpha.com

    Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

    News shared this week that Intellia Therapeutics, Inc.'s pivotal study of candidate lonvo-z is fully enrolled has been greeted warmly by the market, with good reason. NTLA stock remains a compelling B...

    news image

    1 week ago · zacks.com

    NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up

    Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.

    news image

    1 week ago · zacks.com

    Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?

    Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near...

    news image

    2 weeks ago · fool.com

    Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%

    Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested in drops, and instead, she looks at the movement as a chance to increase h...

    news image

    3 weeks ago · invezz.com

    Why big players are pouring millions in THIS biotech stock

    Intellia Therapeutics (NASDAQ: NTLA) has been getting a lot of buzz lately among investors who follow the biotech space. The company uses CRISPR gene editing technology to develop treatments, and whil...

    news image

    1 month ago · seekingalpha.com

    Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

    Intellia Therapeutics, Inc.'s lead gene-editing therapies, Lonvo-z and Nex-z, show best-in-class potential with 'one and done' treatment and strong early efficacy and safety data. Recent safety concer...

    news image

    1 month ago · zacks.com

    Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

    NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.

    news image

    1 month ago · seekingalpha.com

    Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

    Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Brittany Chaves - Corporate Participant David Lebwohl - Executive VP & Chief ...

    news image

    1 month ago · fool.com

    Intellia (NTLA) Q2 Revenue Jumps 106%

    Intellia (NTLA) Q2 Revenue Jumps 106%

    Add to Watchlist